Which has stronger valuation and earnings, GKOS or TMDX?

TransMedics Group has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Glaukos $507.44M 19.78 -$187.69M -$3.25 N/A TransMedics Group $605.49M 4.61 $190.29M $4.40 18.35

Does the media favor GKOS or TMDX?

In the previous week, Glaukos had 9 more articles in the media than TransMedics Group. MarketBeat recorded 28 mentions for Glaukos and 19 mentions for TransMedics Group. Glaukos' average media sentiment score of 0.74 beat TransMedics Group's score of 0.28 indicating that Glaukos is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Glaukos 10 Very Positive mention(s) 4 Positive mention(s) 9 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive TransMedics Group 6 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, LQDA or TMDX?

TransMedics Group has higher revenue and earnings than Liquidia. TransMedics Group is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liquidia $158.32M 49.64 -$68.92M $0.14 631.29 TransMedics Group $605.49M 4.61 $190.29M $4.40 18.35

Does the media favor LQDA or TMDX?

In the previous week, TransMedics Group had 7 more articles in the media than Liquidia. MarketBeat recorded 19 mentions for TransMedics Group and 12 mentions for Liquidia. Liquidia's average media sentiment score of 0.74 beat TransMedics Group's score of 0.28 indicating that Liquidia is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 9 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive TransMedics Group 6 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate TMDX or STVN?

TransMedics Group currently has a consensus target price of $126.27, indicating a potential upside of 56.37%. Given TransMedics Group's higher possible upside, analysts plainly believe TransMedics Group is more favorable than Stevanato Group. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TransMedics Group 1 Sell rating(s) 6 Hold rating(s) 6 Buy rating(s) 0 Strong Buy rating(s) 2.38 Stevanato Group 0 Sell rating(s) 2 Hold rating(s) 2 Buy rating(s) 2 Strong Buy rating(s) 3.00

Does the media prefer TMDX or STVN?

In the previous week, TransMedics Group had 6 more articles in the media than Stevanato Group. MarketBeat recorded 19 mentions for TransMedics Group and 13 mentions for Stevanato Group. Stevanato Group's average media sentiment score of 0.33 beat TransMedics Group's score of 0.28 indicating that Stevanato Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TransMedics Group 6 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Stevanato Group 5 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to BLCO or TMDX?

In the previous week, Bausch + Lomb had 5 more articles in the media than TransMedics Group. MarketBeat recorded 24 mentions for Bausch + Lomb and 19 mentions for TransMedics Group. TransMedics Group's average media sentiment score of 0.28 beat Bausch + Lomb's score of 0.28 indicating that TransMedics Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bausch + Lomb 6 Very Positive mention(s) 3 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral TransMedics Group 6 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer TMDX or MMED?

In the previous week, TransMedics Group had 14 more articles in the media than MiniMed Group. MarketBeat recorded 19 mentions for TransMedics Group and 5 mentions for MiniMed Group. MiniMed Group's average media sentiment score of 0.29 beat TransMedics Group's score of 0.28 indicating that MiniMed Group is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TransMedics Group 6 Very Positive mention(s) 1 Positive mention(s) 7 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral MiniMed Group 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

TransMedics Group (TMDX) Competitors

$80.75 -0.80 (-0.98%)

Closing price 08/4/2026 04:00 PM Eastern

Extended Trading

$73.57 -7.18 (-8.89%)

As of 07:37 AM Eastern

Compare

TMDX vs. GKOS, LQDA, STVN, BLCO, and MMED

Should you buy TransMedics Group stock or one of its competitors? MarketBeat compares TransMedics Group with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with TransMedics Group include Glaukos (GKOS), Liquidia (LQDA), Stevanato Group (STVN), Bausch + Lomb (BLCO), and MiniMed Group (MMED).

How does TransMedics Group compare to Glaukos?

Glaukos (NYSE:GKOS) and TransMedics Group (NASDAQ:TMDX) are both healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, profitability, risk and earnings.

TransMedics Group has higher revenue and earnings than Glaukos. Glaukos is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Glaukos	$507.44M	19.78	-$187.69M	-$3.25	N/A
TransMedics Group	$605.49M	4.61	$190.29M	$4.40	18.35

Glaukos has a beta of 0.78, meaning that its stock price is 22% less volatile than the broader market. Comparatively, TransMedics Group has a beta of 1.9, meaning that its stock price is 90% more volatile than the broader market.

In the previous week, Glaukos had 9 more articles in the media than TransMedics Group. MarketBeat recorded 28 mentions for Glaukos and 19 mentions for TransMedics Group. Glaukos' average media sentiment score of 0.74 beat TransMedics Group's score of 0.28 indicating that Glaukos is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Glaukos	10 Very Positive mention(s)	4 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
TransMedics Group	6 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Glaukos currently has a consensus price target of $177.33, indicating a potential upside of 4.19%. TransMedics Group has a consensus price target of $126.27, indicating a potential upside of 56.37%. Given TransMedics Group's higher probable upside, analysts plainly believe TransMedics Group is more favorable than Glaukos.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Glaukos	1 Sell rating(s)	2 Hold rating(s)	12 Buy rating(s)	0 Strong Buy rating(s)	2.73
TransMedics Group	1 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38

TransMedics Group has a net margin of 27.04% compared to Glaukos' net margin of -30.68%. TransMedics Group's return on equity of 22.38% beat Glaukos' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Glaukos	-30.68%	-6.37%	-4.78%
TransMedics Group	27.04%	22.38%	8.46%

99.0% of Glaukos shares are held by institutional investors. Comparatively, 99.7% of TransMedics Group shares are held by institutional investors. 5.9% of Glaukos shares are held by company insiders. Comparatively, 6.9% of TransMedics Group shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

TransMedics Group beats Glaukos on 11 of the 16 factors compared between the two stocks.

How does TransMedics Group compare to Liquidia?

Liquidia (NASDAQ:LQDA) and TransMedics Group (NASDAQ:TMDX) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, earnings, profitability, media sentiment and analyst recommendations.

TransMedics Group has higher revenue and earnings than Liquidia. TransMedics Group is trading at a lower price-to-earnings ratio than Liquidia, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	49.64	-$68.92M	$0.14	631.29
TransMedics Group	$605.49M	4.61	$190.29M	$4.40	18.35

Liquidia has a beta of 0.58, indicating that its share price is 42% less volatile than the broader market. Comparatively, TransMedics Group has a beta of 1.9, indicating that its share price is 90% more volatile than the broader market.

64.5% of Liquidia shares are owned by institutional investors. Comparatively, 99.7% of TransMedics Group shares are owned by institutional investors. 25.6% of Liquidia shares are owned by company insiders. Comparatively, 6.9% of TransMedics Group shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, TransMedics Group had 7 more articles in the media than Liquidia. MarketBeat recorded 19 mentions for TransMedics Group and 12 mentions for Liquidia. Liquidia's average media sentiment score of 0.74 beat TransMedics Group's score of 0.28 indicating that Liquidia is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	9 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
TransMedics Group	6 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

TransMedics Group has a net margin of 27.04% compared to Liquidia's net margin of 7.74%. Liquidia's return on equity of 46.82% beat TransMedics Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	7.74%	46.82%	7.06%
TransMedics Group	27.04%	22.38%	8.46%

Liquidia currently has a consensus price target of $86.18, indicating a potential downside of 2.49%. TransMedics Group has a consensus price target of $126.27, indicating a potential upside of 56.37%. Given TransMedics Group's higher possible upside, analysts clearly believe TransMedics Group is more favorable than Liquidia.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	3 Strong Buy rating(s)	2.82
TransMedics Group	1 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38

Summary

TransMedics Group beats Liquidia on 10 of the 17 factors compared between the two stocks.

How does TransMedics Group compare to Stevanato Group?

TransMedics Group (NASDAQ:TMDX) and Stevanato Group (NYSE:STVN) are both mid-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, institutional ownership, media sentiment, earnings, risk, analyst recommendations, dividends and valuation.

TransMedics Group has a net margin of 27.04% compared to Stevanato Group's net margin of 11.76%. TransMedics Group's return on equity of 22.38% beat Stevanato Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransMedics Group	27.04%	22.38%	8.46%
Stevanato Group	11.76%	10.27%	6.08%

TransMedics Group has a beta of 1.9, suggesting that its stock price is 90% more volatile than the broader market. Comparatively, Stevanato Group has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market.

99.7% of TransMedics Group shares are held by institutional investors. 6.9% of TransMedics Group shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

TransMedics Group has higher earnings, but lower revenue than Stevanato Group. TransMedics Group is trading at a lower price-to-earnings ratio than Stevanato Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransMedics Group	$605.49M	4.61	$190.29M	$4.40	18.35
Stevanato Group	€1.34B	4.46	€158.21M	€0.59	33.52

In the previous week, TransMedics Group had 6 more articles in the media than Stevanato Group. MarketBeat recorded 19 mentions for TransMedics Group and 13 mentions for Stevanato Group. Stevanato Group's average media sentiment score of 0.33 beat TransMedics Group's score of 0.28 indicating that Stevanato Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TransMedics Group	6 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Stevanato Group	5 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

TransMedics Group currently has a consensus target price of $126.27, indicating a potential upside of 56.37%. Given TransMedics Group's higher possible upside, analysts plainly believe TransMedics Group is more favorable than Stevanato Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransMedics Group	1 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38
Stevanato Group	0 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

TransMedics Group beats Stevanato Group on 12 of the 17 factors compared between the two stocks.

How does TransMedics Group compare to Bausch + Lomb?

Bausch + Lomb (NYSE:BLCO) and TransMedics Group (NASDAQ:TMDX) are both mid-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their dividends, media sentiment, institutional ownership, profitability, earnings, analyst recommendations, valuation and risk.

TransMedics Group has lower revenue, but higher earnings than Bausch + Lomb. Bausch + Lomb is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bausch + Lomb	$5.10B	1.17	-$360M	-$0.48	N/A
TransMedics Group	$605.49M	4.61	$190.29M	$4.40	18.35

Bausch + Lomb has a beta of 0.56, indicating that its stock price is 44% less volatile than the broader market. Comparatively, TransMedics Group has a beta of 1.9, indicating that its stock price is 90% more volatile than the broader market.

In the previous week, Bausch + Lomb had 5 more articles in the media than TransMedics Group. MarketBeat recorded 24 mentions for Bausch + Lomb and 19 mentions for TransMedics Group. TransMedics Group's average media sentiment score of 0.28 beat Bausch + Lomb's score of 0.28 indicating that TransMedics Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bausch + Lomb	6 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
TransMedics Group	6 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

Bausch + Lomb currently has a consensus target price of $18.75, suggesting a potential upside of 12.58%. TransMedics Group has a consensus target price of $126.27, suggesting a potential upside of 56.37%. Given TransMedics Group's stronger consensus rating and higher possible upside, analysts clearly believe TransMedics Group is more favorable than Bausch + Lomb.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bausch + Lomb	1 Sell rating(s)	8 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.29
TransMedics Group	1 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38

11.1% of Bausch + Lomb shares are owned by institutional investors. Comparatively, 99.7% of TransMedics Group shares are owned by institutional investors. 1.5% of Bausch + Lomb shares are owned by insiders. Comparatively, 6.9% of TransMedics Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

TransMedics Group has a net margin of 27.04% compared to Bausch + Lomb's net margin of -3.21%. TransMedics Group's return on equity of 22.38% beat Bausch + Lomb's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bausch + Lomb	-3.21%	4.14%	1.93%
TransMedics Group	27.04%	22.38%	8.46%

Summary

TransMedics Group beats Bausch + Lomb on 14 of the 16 factors compared between the two stocks.

How does TransMedics Group compare to MiniMed Group?

TransMedics Group (NASDAQ:TMDX) and MiniMed Group (NASDAQ:MMED) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their dividends, risk, earnings, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

TransMedics Group presently has a consensus target price of $126.27, indicating a potential upside of 56.37%. MiniMed Group has a consensus target price of $21.62, indicating a potential upside of 13.83%. Given TransMedics Group's higher possible upside, equities analysts plainly believe TransMedics Group is more favorable than MiniMed Group.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransMedics Group	1 Sell rating(s)	6 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.38
MiniMed Group	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

TransMedics Group has higher earnings, but lower revenue than MiniMed Group. MiniMed Group is trading at a lower price-to-earnings ratio than TransMedics Group, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransMedics Group	$605.49M	4.61	$190.29M	$4.40	18.35
MiniMed Group	$3.10B	1.72	-$190.97M	-$0.68	N/A

In the previous week, TransMedics Group had 14 more articles in the media than MiniMed Group. MarketBeat recorded 19 mentions for TransMedics Group and 5 mentions for MiniMed Group. MiniMed Group's average media sentiment score of 0.29 beat TransMedics Group's score of 0.28 indicating that MiniMed Group is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TransMedics Group	6 Very Positive mention(s)	1 Positive mention(s)	7 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
MiniMed Group	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

99.7% of TransMedics Group shares are owned by institutional investors. Comparatively, 19.7% of MiniMed Group shares are owned by institutional investors. 6.9% of TransMedics Group shares are owned by insiders. Comparatively, 2.2% of MiniMed Group shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

TransMedics Group has a net margin of 27.04% compared to MiniMed Group's net margin of 0.00%. TransMedics Group's return on equity of 22.38% beat MiniMed Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransMedics Group	27.04%	22.38%	8.46%
MiniMed Group	N/A	N/A	N/A

Summary

TransMedics Group beats MiniMed Group on 11 of the 15 factors compared between the two stocks.

Get TransMedics Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TMDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TMDX vs. The Competition

Export

Metric	TransMedics Group	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.82B	$5.78B	$6.83B	$12.77B
Dividend Yield	N/A	1.78%	2.60%	10.01%
P/E Ratio	18.35	23.44	279.15	25.53
Price / Sales	4.61	44.13	587.36	92.31
Price / Cash	20.77	32.60	72.11	49.39
Price / Book	5.86	6.13	13.06	6.11
Net Income	$190.29M	$150.91M	$3.48B	$347.58M
7 Day Performance	3.53%	5.99%	3.38%	4.91%
1 Month Performance	17.27%	1.01%	-2.81%	-2.06%
1 Year Performance	-35.78%	9.10%	73.07%	21.03%

TransMedics Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TMDX TransMedics Group	4.4949 of 5 stars	$80.75 -1.0%	$126.27 +56.4%	-37.2%	$2.82B	$605.49M	18.35	210	Trending News Earnings Report Analyst Forecast Gap Down
GKOS Glaukos	1.8997 of 5 stars	$150.54 -2.0%	$154.85 +2.9%	+94.5%	$8.84B	$507.44M	N/A	1,094	Earnings Report
LQDA Liquidia	3.1404 of 5 stars	$86.29 +0.1%	$86.18 -0.1%	+353.7%	$7.67B	$158.32M	616.44	50	Upcoming Earnings Gap Up
STVN Stevanato Group	2.9568 of 5 stars	€19.85 +0.9%	N/A	-22.7%	€6.01B	€1.34B	33.65	6,010	Trending News
BLCO Bausch + Lomb	3.5906 of 5 stars	$16.40 +1.4%	$18.00 +9.8%	+21.0%	$5.85B	$5.10B	N/A	13,000	Trending News Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TMDX) was last updated on 8/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TransMedics Group (TMDX) Competitors

TMDX vs. GKOS, LQDA, STVN, BLCO, and MMED

How does TransMedics Group compare to Glaukos?

Summary

How does TransMedics Group compare to Liquidia?

Summary

How does TransMedics Group compare to Stevanato Group?

Summary

How does TransMedics Group compare to Bausch + Lomb?

Summary

How does TransMedics Group compare to MiniMed Group?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TMDX vs. The Competition

TransMedics Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TransMedics Group (TMDX) Competitors

TMDX vs. GKOS, LQDA, STVN, BLCO, and MMED

How does TransMedics Group compare to Glaukos?

Which has stronger valuation and earnings, GKOS or TMDX?

Which has more volatility and risk, GKOS or TMDX?

Does the media favor GKOS or TMDX?

Do analysts recommend GKOS or TMDX?

Is GKOS or TMDX more profitable?

Do insiders & institutionals believe in GKOS or TMDX?

Summary

How does TransMedics Group compare to Liquidia?

Which has preferable valuation and earnings, LQDA or TMDX?

Which has more risk and volatility, LQDA or TMDX?

Do insiders and institutionals have more ownership in LQDA or TMDX?

Does the media favor LQDA or TMDX?

Is LQDA or TMDX more profitable?

Do analysts rate LQDA or TMDX?

Summary

How does TransMedics Group compare to Stevanato Group?

Is TMDX or STVN more profitable?

Which has more risk & volatility, TMDX or STVN?

Do insiders & institutionals believe in TMDX or STVN?

Which has higher earnings & valuation, TMDX or STVN?

Does the media prefer TMDX or STVN?

Do analysts rate TMDX or STVN?

Summary

How does TransMedics Group compare to Bausch + Lomb?

Which has higher valuation and earnings, BLCO or TMDX?

Which has more risk and volatility, BLCO or TMDX?

Does the media refer more to BLCO or TMDX?

Do analysts recommend BLCO or TMDX?

Do insiders and institutionals have more ownership in BLCO or TMDX?

Is BLCO or TMDX more profitable?

Summary

How does TransMedics Group compare to MiniMed Group?

Do analysts prefer TMDX or MMED?

Which has better valuation & earnings, TMDX or MMED?

Does the media prefer TMDX or MMED?

Do institutionals and insiders believe in TMDX or MMED?

Is TMDX or MMED more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TMDX vs. The Competition

TransMedics Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools